SCHEMBL5664153

SCHEMBL5664153

FC(F)(F)c1ccccc1-n1ccc2ccccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.47
ALDH1A1 P00352 3/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
LMNA P02545 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
MAPK1 P28482 1/20 0.47
CYP2C19 P33261 1/20 0.47
PMP22 Q01453 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
BIRC5 O15392 1/20 0.43
PRKD3 O94806 1/20 0.42
PRKCG P05129 1/20 0.42
PRKCB P05771 1/20 0.42
PRKCA P17252 1/20 0.42
PRKACA P17612 1/20 0.42
PRKACG P22612 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29042382 0.81 BIRC5 (0.37) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL146857 0.81 MAPT (0.41) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL28679163 0.79 EPHX2 (0.46) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL27403765 0.78 MAPT (0.38) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL30394203 0.78 ENPP3 (0.48) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL27400872 0.78 ENPP3 (0.48) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL29480963 0.77 POLB (0.57) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL16462544 0.77 POLB (0.50) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL6840252 0.77 TTR (0.52) CYP2C9KDM4E
SCHEMBL23075523 0.76 BIRC5 (0.47) MAPTALDH1A1BIRC5PRKD3PRKCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043080-A1 Substituted anilinic piperidines as MCH selective antagonists MARZABADI MOHAMMAD R 2007-02-22 US disclosed
CN-1671386-A Substituted anilinic piperidines as MCH selective antagonists LUNDBECK & CO AS H (DK) 2005-09-21 CN disclosed
EP-1411942-A4 SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS SYNAPTIC PHARMA CORP (US) 2005-01-26 EP disclosed
EP-1411942-A1 SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS Synaptic Pharmaceutical Corporation (US) 2004-04-28 EP disclosed
WO-2003004027-A1 SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043080-A1 Substituted anilinic piperidines as MCH selective antagonists MCHR1, MCHR2, MC1R MAPT 2336/4885ALDH1A1 620/4885KMT2A 1037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.